{"nctId":"NCT04218123","briefTitle":"Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes","startDateStruct":{"date":"2020-02-05","type":"ACTUAL"},"conditions":["Meniere Disease"],"count":40,"armGroups":[{"label":"Venlafaxine Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Venlafaxine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral tablet"]}],"interventions":[{"name":"Venlafaxine","otherNames":[]},{"name":"Placebo oral tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Study subjects will be prospectively recruited from the population of patients presenting with dizziness to our tertiary, multidisciplinary, vestibular-focused, neurotology clinic. Subjects must meet the following inclusion criteria:\n\n* be 18 years of age or older;\n* have definite MD as defined by the Barany Society 2015 international consensus statement;\n* have active MD with at least 2 vertigo episodes in the month prior to enrollment; and score at least 36 on the Dizziness Handicap Inventory (DHI), representing at least moderate handicap.\n\nPatients with the following will be excluded:\n\n* other concurrent vestibular or balance disorder (especially those with vestibular migraine-related vertigo episodes despite not meeting diagnostic criteria for vestibular migraine);\n* currently taking venlafaxine, SSRIs, or SNRIs;\n* history of medical (e.g. gentamicin) or surgical (e.g. labyrinthectomy) vestibular ablative treatment;\n* history of otologic, lateral skull base, or brain surgery;\n* history of radiation to the head or neck;\n* known neurologic disorder affecting cognition;\n* currently taking another serotonin modulating medication;\n* seizures;\n* stroke;\n* myocardial infarction;\n* hepatic or renal impairment;\n* hyperlipidemia;\n* coagulopathy;\n* psychiatric disorder other than anxiety or depression;\n* glaucoma;\n* uncontrolled hypertension;\n* pregnancy or intention of pregnancy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Vertigo Episodes","description":"Patients will be keeping a diary throughout the study period and beyond.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.41","spread":"4.44"},{"groupId":"OG001","value":"5.03","spread":"4.57"},{"groupId":"OG002","value":"13.78","spread":"10.05"}]}]}]},{"type":"PRIMARY","title":"Severity of Vertigo","description":"The study team will use a modified version of vertigo control classification because the treatment phases are 2 months long and the study team will not be able to wait 18-24 months after treatment to assess efficacy per academy guidelines. Previous studies have defined four categories of response to treatment: 1) very good response if more than 75% reduction in vertigo spells frequency and/or intensity, 2) good response if 50-75% reduction, 3) fair response if 25-50% reduction, and 4) poor response if less than 25% reduction.\n\nThe vertigo classes will be defined as follows; Class A: 0 (complete control of vertigo) Class B: 0-40 or \\>60% reduction in mean vertigo episode severity (good control of vertigo) Class C: 41-80 or 20-60% reduction in severity (fair control of vertigo) Class D: 81-120 or -20-20% reduction in severity (no change in vertigo) Class E: \\>120 or \\>20% worsening in severity (worse vertigo)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Score on The Medical Outcomes Study 20-item Short Form Health Survey","description":"The Medical Outcomes Study 20-item Short Form Health Survey is a 20-item general health questionnaire to assess quality of life in chronic diseases. It assesses 6 areas of health: physical functioning, role functioning, social functioning, mental health, health perceptions, and pain. Each score ranges between 0 and 100, with 100 indicating best possible function and 0 the worst possible function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.92","spread":"3.34"},{"groupId":"OG001","value":"14.54","spread":"3.42"},{"groupId":"OG002","value":"13.81","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"1.62"},{"groupId":"OG001","value":"4.6","spread":"1.61"},{"groupId":"OG002","value":"4.38","spread":"1.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.24","spread":"6.79"},{"groupId":"OG001","value":"22","spread":"5.95"},{"groupId":"OG002","value":"20.95","spread":"6.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.38","spread":"1.67"},{"groupId":"OG001","value":"4.54","spread":"1.44"},{"groupId":"OG002","value":"3.84","spread":"1.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.95","spread":"4.91"},{"groupId":"OG001","value":"16.17","spread":"5.46"},{"groupId":"OG002","value":"15.07","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.44"},{"groupId":"OG001","value":"2.74","spread":"1.42"},{"groupId":"OG002","value":"2.76","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Change in Score on The Meniere's Disease Patient-Oriented Symptom Index (MDPOSI)","description":"The Meniere's Disease Patient-Oriented Symptom Index is a 23-item survey developed as a MD-specific tool to assess the impact of MD symptoms on patients' lives. The score ranges from 0 to 100 with the higher score indicating an active disease with significant impact on function and quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.81","spread":"15.59"},{"groupId":"OG001","value":"46.31","spread":"16.32"},{"groupId":"OG002","value":"50.68","spread":"13.66"}]}]}]},{"type":"SECONDARY","title":"Change in Score on Penn State Worry Questionnaire (PSWQ)","description":"The PSWQ is a 16-item survey for assessment of anxiety which has been used to identify generalized anxiety disorder. Scores range from 16 (Low worry) to 80 (high worry). A score higher than 60 is indicative of significant anxiety and risk for an anxiety disorder","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.35","spread":"14.36"},{"groupId":"OG001","value":"45.63","spread":"13.48"},{"groupId":"OG002","value":"47.16","spread":"14.11"}]}]}]},{"type":"SECONDARY","title":"Change in Score on Patient Health Questionnaire (PHQ9)","description":"The Patient Health Questionnaire is a 9-item survey which assesses the severity of depression. A low score is indicative of little to no depressive symptoms, and a high score is indicative of Moderately severe to severe depressive symptoms. Scores range from 0 to 27 with scores higher than 20 indicative of significant risk for depression and scores below 10 indicative at most of a mild depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.49","spread":"5.27"},{"groupId":"OG001","value":"7.17","spread":"5.73"},{"groupId":"OG002","value":"7.43","spread":"5.32"}]}]}]},{"type":"SECONDARY","title":"Change in Score on Cognitive Failure Questionnaire (CFQ)","description":"The Cognitive Failure Questionnaire is a 25-item survey which assesses cognitive and executive function not tied to any specific disease state. It aims to assess perception, memory, and motor function in everyday tasks.The score ranges from 0 to 100 The higher score on the CFQ, the more frequent the cognitive failures experienced by the subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.92","spread":"16.35"},{"groupId":"OG001","value":"36.4","spread":"17.63"},{"groupId":"OG002","value":"36.14","spread":"18.18"}]}]}]},{"type":"SECONDARY","title":"Change in Score on Neuropsychological Vertigo Inventory (NVI)","description":"The English version of the Neuropsychological Vertigo Inventory consists of 28-items with a 5-point Likert scale for each question. It is a cognitive assessment specific to patients with dizziness. The NVI assesses 7 domains of cognition: space perception, attention, time perception, memory, emotional, visual/ocular and motor. The score ranges from 0 to 140. The higher the score on the NVI the worse the cognitive function of the subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.41","spread":"18.67"},{"groupId":"OG001","value":"63.31","spread":"17.78"},{"groupId":"OG002","value":"65.11","spread":"20.01"}]}]}]},{"type":"SECONDARY","title":"Change in Score on Dizziness Handicap Inventory (DHI)","description":"The Dizziness Handicap Inventory is a 25-item questionnaire of self-perceived handicap from dizziness.There are 7 questions in the physical domain, 9 in the emotional domain, and 8 in the functional domain. It is scored from 0 (no perceived disability) to 100 (maximum perceived disability).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.46","spread":"24.2"},{"groupId":"OG001","value":"45.2","spread":"20.77"},{"groupId":"OG002","value":"55.62","spread":"16.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Nausea/vomiting","Dry mouth","Decreased Appetite","Sweating","Insomnia"]}}}